Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07579429 · ClinicalTrials.gov registry record · Phase 2
Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
A Phase 2 study, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT07579429 is a Phase 2 study that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 10 participants.
The verdict
NCT07579429, a Phase 2 study, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an open-label, phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent. There will be two cohorts enrolled at the same time to measure the effect of nicotinamide riboside and pterostilbene at different doses. The primary goals of the study are: * to assess if study drug improves cytopenias in patients * to determine safety of the study drug in patients
Interventions
- DRUG Nicotinamide Riboside
- DRUG Pterostilbene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-05-20 |
| Est. Completion | 2030-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07579429
The ClinicalTrials.gov registry entry for NCT07579429 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nicotinamide Riboside is the first listed.
NCT07579429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07579429 about?
NCT07579429 is a clinical study titled "Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)". This is an open-label, phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent. There will be two cohorts enrolled at the same time to measure the effect of nicotinamide riboside and pterostilbene at different doses. The primary goals of the study are: * to asse...
What is the current status of trial NCT07579429?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2026-05-20. Estimated completion is 2030-12-18.
What interventions are being tested in trial NCT07579429?
The interventions under investigation include: Nicotinamide Riboside (DRUG), Pterostilbene (DRUG).
Who is sponsoring clinical trial NCT07579429?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.